Remdesivir to be administered on medical prescription to severe COVID-19 patients: Centre to SC

Remdesivir to be administered on medical prescription to severe COVID-19 patients: Centre to SC [ad_1]

Antiviral drug Remdesivir is to be administered solely after a medical prescription and restricted to severe situation of COVID-19 sufferers strictly as per medical protocol, the Centre advised the Supreme Court on Friday.

A bench headed by Justice D Y Chandrachud was knowledgeable that there’s a rising demand from some quarters to allow using Remdesivir even when an individual is taking therapy at his own residence below his personal personal medical supervision.

“The argument in assist of this demand is to the impact that allowing Remdesivir would reduce the stress upon hospitals and a affected person can take therapy from his personal doctor at dwelling. This argument, at first blush, seems to be a pretty argument.

“More particularly when Remdesivir is to be administered only upon a medical prescription and by a the qualified doctor attending to the patient at his residence…the use of Remdevisir must remain limited to severe condition COVID-19 patients strictly as per medical protocol,” the Centre advised the federal government in its affidavit.

It stated that Remdesivir is listed as “investigational therapy” within the National Clinical Management Protocol: COVID-19 which is ready by a group of eminent consultants of the assorted fields.

As per the Clinical Management Protocol of Covid-19 ready by a group of eminent consultants within the area, it’s only “moderate to severe cases” through which administration of Remdesivir can to be thought-about that too relying upon the scientific judgment of the treating physician which, in flip, would rely on a number of well being parameters of every affected person, Centre stated.

It stated that to preserve a examine on the pricing of the drug the National Pharmaceutical Pricing Authority, on April 17, 2021, launched the revised most retail value (MRP) for 100mg/Vial of Remdesivir, as communicated by the licensed producers, bringing down the price of all the key manufacturers to under Rs 3,500 per vial to guarantee affordability of the injection among the many lots.

The bench, additionally comprising Justices L Nageswara Rao and S Ravindra Bhat, on April 22 took word of the pandemic scenario due to sudden surge in COVID-19 instances as additionally in mortality and stated it anticipated the Centre to come out with a “national plan” to cope with the distribution of important providers and provides, together with oxygen and medicines.


Source link

#Remdesivir #administered #medical #prescription #severe #COVID19 #sufferers #Centre

Related Articles

Stay Connected

- Advertisement -

Latest Articles

%d bloggers like this: